Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment. Defence Therapeutics’ pipeline comprises multiple preclinical and early-stage clinical candidates targeting indications such as melanoma, head and neck cancers, and breast cancer. Through preclinical validation and investigational new drug (IND) filings, the company seeks to advance these candidates into human trials and ultimately secure regulatory approvals.
Defence Therapeutics serves North American markets, engaging with Health Canada and the U.S. Food and Drug Administration as it progresses its programs. The company collaborates with a range of academic research centers and contract research organizations to support preclinical studies and toxicology assessments. These partnerships are intended to streamline development timelines and bolster scientific rigor across its immuno-oncology portfolio.
The company’s management team brings together expertise in biotechnology, pharmaceutical development, and clinical research. At the helm is President and Chief Executive Officer Louise Audet, who oversees strategic planning, corporate development, and investor relations. Under her leadership, Defence Therapeutics continues to advance its mission of delivering next-generation cancer immunotherapies to patients in need.
AI Generated. May Contain Errors.
